Balaxi Pharmaceuticals Ltd's Q4FY25 Quarterly Results

Result Summary

• Balaxi Pharmaceuticals Ltd reported a 24.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 27.9%.
• Its expenses for the quarter were down by 33.1% QoQ and 31.4% YoY.
• The net profit increased 103.9% QoQ and increased 34.9% YoY.
• The earnings per share (EPS) of Balaxi Pharmaceuticals Ltd stood at 10.4 during Q4FY25.

Financial Statments for Q4FY25

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Balaxi Pharmaceuticals Ltd is primarily engaged in the manufacturing and distribution of pharmaceutical products. The company operates within the pharmaceutical industry, focusing on delivering a broad range of medications and health-related solutions. As of the latest available information, no recent major developments specific to Balaxi Pharmaceuticals Ltd have been provided. However, like many companies in the pharmaceutical sector, Balaxi may be subject to trends such as regulatory changes, advancements in medical research, and shifts in market demand.

Revenue

For the fourth quarter of the fiscal year 2025 (Q4FY25), Balaxi Pharmaceuticals Ltd reported a total income of ₹58.05 crores. This represents a decrease of 24.8% from the previous quarter (Q3FY25), where the total income was ₹77.23 crores. When compared year-over-year (YoY) to the fourth quarter of the fiscal year 2024 (Q4FY24), where the total income was ₹80.46 crores, the company experienced a decline of 27.9%. These changes reflect variations in revenue generation compared to both the previous quarter and the same quarter the previous year.

Profitability

During Q4FY25, Balaxi Pharmaceuticals Ltd recorded a Profit Before Tax (PBT) of ₹11.49 crores, which is an increase of 89.3% compared to Q3FY25 when the PBT was ₹6.07 crores. Year-over-year, there was a slight increase of 3.8% from Q4FY24, where the PBT was ₹11.07 crores. The Profit After Tax (PAT) for Q4FY25 was ₹10.93 crores, marking a significant growth of 103.9% from the previous quarter's PAT of ₹5.36 crores. Compared to Q4FY24, which posted a PAT of ₹8.10 crores, there was a YoY increase of 34.9%. Earnings Per Share (EPS) saw an increase to ₹10.40 in Q4FY25 from ₹1.00 in Q3FY25, a substantial rise of 940.0%. Compared to Q4FY24, where the EPS was ₹7.90, there was a YoY increase of 31.6%.

Operating Metrics

In Q4FY25, Balaxi Pharmaceuticals Ltd reported total expenses of ₹47.64 crores, which decreased by 33.1% from the preceding quarter's total expenses of ₹71.16 crores. Year-over-year, this figure shows a decrease of 31.4% from Q4FY24, where total expenses were ₹69.40 crores. The tax outlay for Q4FY25 was ₹0.56 crores, marking a decrease of 21.1% from ₹0.71 crores in Q3FY25. Compared to Q4FY24, when the tax expense was ₹2.97 crores, there was a significant YoY decrease of 81.1%. These financial metrics indicate variations in the company’s expenditure and tax obligations across different reporting periods.